Zhang Tianhang, Lv Haitao, Li Jiasong, Zhang Shasha, Zhang Jingjing, Wang Siqi, Wang Yingnan, Guo Zhanjun
Department of Rheumatology and Immunology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Front Immunol. 2024 Dec 24;15:1503316. doi: 10.3389/fimmu.2024.1503316. eCollection 2024.
The occurrence of immune-related adverse events (irAEs) seemed to be associated with better outcomes in advanced gastric cancer (AGC) patients. However, research focusing on the impact of the single-organ irAE (uni-irAE) or multi-organ irAEs (multi-irAEs) on the AGC outcome is relatively limited. In this study, we investigated individually the impact of the different irAEs on AGC survival as well as the co-occurrence patterns of multi-irAEs.
The uni-irAE, multi-irAEs, and non-irAE were identified based on National Comprehensive Cancer Network (NCCN) guidelines. ICI efficacy for the disease control rate (DCR) and the objective response rate (ORR) was assessed based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. The association for the irAEs with progression-free survival (PFS) or overall survival (OS) was analyzed using the Kaplan-Meier method and Cox regression model. We also performed pairwise correlation analysis to identify co-occurrence patterns of multi-organ irAEs.
A total of 288 patients including 175 non-irAE, 73 uni-irAE, and 40 multi-irAE patients were evaluated for their association with AGC outcome. The irAEs patients displayed higher DCR (78.8% vs. 67.4%, =0.037) when compared with those of non-irAE patients, and both uni-irAE patients (82.2% vs. 67.4%, =0.019) and multi-irAE patients (72.5% vs. 67.4%, =0.534) showed higher DCR than that of non-irAE patients. The multivariate analyses revealed that multi-irAEs was an independent risk factor for PFS (hazard ratio [HR] of 0.63, 95% confidence interval [CI] 0.410.96, =0.031) and OS (HR 0.47, 95% CI 0.290.76, =0.002), whereas the survival association for uni-irAE was not obtained. The analysis of the co-occurrence patterns for multi-irAEs revealed that the thyroid, adrenal gland, heart, skin, and lung irAEs exhibited a high risk of co-occurrence of multi-irAEs. The multivariate Cox regression analysis for organ-specific irAEs revealed that patients experiencing thyroid, adrenal gland, and skin irAEs had favorable survival outcomes compared with those without these irAEs.
Multi-irAEs and some organ-specific irAEs can be used as predictive indicators for ICI treatment efficacy in AGC patients. The thyroid, adrenal gland, heart, skin, and lung irAEs are often accompanied by multi-irAE occurrence.
免疫相关不良事件(irAEs)的发生似乎与晚期胃癌(AGC)患者更好的预后相关。然而,聚焦于单器官irAE(uni-irAE)或多器官irAEs(multi-irAEs)对AGC预后影响的研究相对有限。在本研究中,我们分别调查了不同irAEs对AGC生存的影响以及multi-irAEs的共现模式。
根据美国国立综合癌症网络(NCCN)指南确定uni-irAE、multi-irAEs和非irAE。基于实体瘤疗效评价标准(RECIST)1.1版评估免疫检查点抑制剂(ICI)对疾病控制率(DCR)和客观缓解率(ORR)的疗效。使用Kaplan-Meier方法和Cox回归模型分析irAEs与无进展生存期(PFS)或总生存期(OS)的关联。我们还进行了成对相关性分析以确定多器官irAEs的共现模式。
共评估了288例患者,包括175例非irAE患者、73例uni-irAE患者和40例multi-irAEs患者与AGC预后的关联。与非irAE患者相比,irAEs患者显示出更高的DCR(78.8%对67.4%,P=0.037),并且uni-irAE患者(82.2%对67.4%,P=0.019)和multi-irAEs患者(72.5%对67.4%,P=0.534)均显示出比非irAE患者更高的DCR。多变量分析显示,multi-irAEs是PFS(风险比[HR]为0.63,95%置信区间[CI]为0.410.96,P=0.031)和OS(HR 0.47,95%CI为0.290.76,P=0.002)的独立危险因素,而未获得uni-irAE与生存的关联。对multi-irAEs共现模式的分析显示,甲状腺、肾上腺、心脏、皮肤和肺部irAEs表现出multi-irAEs共现的高风险。针对器官特异性irAEs的多变量Cox回归分析显示,与未发生这些irAEs的患者相比,发生甲状腺、肾上腺和皮肤irAEs的患者具有良好的生存结局。
Multi-irAEs和一些器官特异性irAEs可作为AGC患者ICI治疗疗效的预测指标。甲状腺、肾上腺、心脏、皮肤和肺部irAEs常伴随multi-irAEs发生。